UVA Health System frequently opens new clinical trials, offering your patients the latest investigational treatments.
For a complete list of active cancer trials and study coordinator contact information, visit our newly launched Find a Clinical Trial website. If you have patients who may be eligible to participate in a cancer clinical trial, please email cancerclinicaltrials@virginia.edu.
Transplant (IRB-HSR #20915)
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological Malignancies (NCT02730299)
Primary Investigator: Leonid Volodin
B-cell Acute Lymphoblastic Leukemia (IRB-HSR #21417)
Phase I Study of Inotuzumab Ozogamicin with 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Younger Adults Ages 18-55 with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) (NCT03962465)
Primary Investigator: Michael Douvas
Clinical Research Coordinator: Cara Hanby
Genitourinary Oncology (IRB-HSR #21450)
A Multicenter Phase II Study Testing the Activity of Olaparib and AZD6738 (ATR Inhibitor) in Metastatic Castration-Resistant Prostate Cancer (NCT03787680)
Primary Investigator: Michael Devitt
Clinical Research Coordinator: Julio Torres
Melanoma (IRB-HSR #21850)
Pilot Evaluation of Focused Ultrasound Ablation and Focused Ultrasound Ablation Plus PD-1 Antibody Blockade in Advanced Solid Tumors (NCT04116320)
Primary Investigator: Lynn Dengel
Clinical Research Coordinator: Rachael Reed
Colorectal Cancer (IRB-HSR #21923)
A Phase Ib/2, Open-Label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-Line Therapy in Metastatic Microsatellite-Stable Colorectal Cancer (COLUMBIA-1) (NCT04068610)
Primary Investigator: Matthew Reilley
Clinical Research Coordinator: Sallie Mannen
Breast Oncology (IRB-HSR #21822)
COX Inhibition and Biomarkers of Response During Neoadjuvant Chemoendocrine Therapy for Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Stage I-III Breast Cancer (NCT04038489)
Primary Investigator: Patrick Dillon
Clinical Research Coordinator: Jake Boyd
Hematologic Malignancies IRB-HSR #21776
Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age. PrECOG Protocol Number: PrE0405. (NCT03834688)
Primary Investigator: Craig Portell
Thoracic Oncology (IRB-HSR #21811)
Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 and a CTLA-4 inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects with Non-small Cell Lung Cancer or Urothelial Cancer (NCT03989362)
Primary Investigator: Ryan Gentzler
Clinical Research Coordinator: Gracie Hockenberry
Thoracic Oncology (IRB-HSR #21913)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study) (NCT03971474)
Primary Investigator: Richard Hall
Clinical Research Coordinator: Gracie Hockenberry
Dementia with Lewy Bodies (IRB-HSR #21673)
EIP19-NFD-501: A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of the Oral P38 Alpha Kinase Inhibitor Neflamapimod in Dementia with Lewy Bodies (DLB) (NCT04001517)
Primary Investigator: Binit Shah
Clinical Research Coordinator: Colleen Webber
